Navigation Links
Researchers find function of proteins that can enhance the progression of viruses and cancer cells
Date:8/16/2010

In a discovery that has implications for developing treatments against cancer and potentially deadly viruses, researchers at SUNY Downstate Medical Center have discovered the function of proteins that can enhance the progression of certain viruses and cancer cells. Their findings were published in the journal Genes and Development.

According to Tatyana Pestova, PhD, DSc, assistant professor of cell biology, and Christopher Hellen, DPhil, associate professor of cell biology, "The significance of our work is that we have identified proteins (Ligatin, MCT-1 and DENR) that can substitute for the activity of one or more canonical initiation factors in the initiation and ribosome recycling stages of eukaryotic protein synthesis. These factors act either individually (Ligatin) or together (MCT-1 and DENR) to substitute for eIF2 in promoting initiation of translation on a specific subset of mRNAs under conditions when translation is globally repressed. These observations are clinically relevant with respect to (a) viral infections and (b) cancer pathogenesis." Maxim Skabkin, PhD, a research scientist in the Department of Cell Biology, is the lead author of the paper.

The cellular response to counteract viral infection involves activation of pathways that "shut off" translation by phosphorylating eIF2, preventing it from recruiting initiator tRNA to the ribosome. Some viral mRNAs continue to be translated at the same or a reduced rate under these conditions, including those of Hepatitis C virus, human rotaviruses (a major cause of acute, frequently fatal, gastroenteritis in infants), coronaviruses (including SARS), and alphaviruses (e.g. Sindbis virus).

The authors reported a novel eIF2-independent mode of translation initiation in which Ligatin alone or MCT-1 and DENR together promote binding of initiator tRNA to specific ribosomal initiation complexes, and found that this mechanism functions very efficiently for Sindbis virus and to a lesser extent for Hepatitis C virus and related pathogenic viruses. This novel initiation mechanism is thus a potential target for therapeutic inhibition to counteract viral infection.

This eIF2-independent mode of initiation is likely a cellular mechanism that has been co-opted by viruses. MCT-1 (multiple copies in T-cell lymphoma-1) has previously been reported to act at the translational level to increase cell proliferation and survival and to enhance the invasiveness of cancer cells, but how it functions was not known. It is an oncogene that is over-expressed in lung cancer tissues and has been implicated in the development of human T-cell and B-cell lymphomas.

Dr. Hellen adds, "Our identification of a specific role for MCT-1 in promoting eIF2-independent initiation on specific mRNAs could account for its oncogenic activity by promoting the preferential translation of a subset of cancer-related mRNAs into proteins that promote angiogenesis, tumor cell survival, transformation, and metastasis."


'/>"/>

Contact: Ron Najman
ron.najman@downstate.edu
718-270-2696
SUNY Downstate Medical Center
Source:Eurekalert

Related medicine news :

1. In NIH-funded study, researchers uncover step in brain events leading up to addiction
2. Researchers develop magnetic molecular machines to deliver drugs to unhealthy cells
3. UCLA researchers discover protein that shuttles RNA into cell mitochondria
4. Help wanted: Highly cited researchers needed for high-ranking positions at research institutions
5. NIST researchers measure high infrared power levels from some green lasers
6. Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts
7. Researchers develop advanced search tool to help physicians sort and retrieve vital EMR data
8. Researchers identify key enzyme in DNA repair pathway
9. Researchers study benefits of white button mushrooms
10. Use of decision-aid program increases safety for women experiencing abuse, researchers find
11. Researchers uncover biological rationale for why intensive lupus treatment works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: